stockrow
Friday 6 November 2026
Export ASND’s income statement to Excel — free account
Ascendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
256.60
3.15
+1.24%
Follow ASND
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
15.86 | 20.25 | 24.87 | 125.55 | 800.73 | 1,062.89 | 431.91 | 205.98 | 773.87 | 103.77 |
Altman Z-Score |
2.02 | 0.08 | (0.58) | 1.50 | 16.15 | 29.69 | 42.18 | 31.26 | 27.63 | 22.67 |
P/FCF ratio |
251.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(7.38) | (7.90) | (8.84) | (4.17) | 1.83 | 5.15 | 8.14 | 5.50 | 6.27 | 19.82 |
P/Operating CF |
154.27 | (88.07) | (165.50) | (40.85) | (50.11) | (85.84) | (115.21) | (58.65) | (55.50) | (29.34) |
Beneish M-Score |
(2.51) | (1.23) | 0.47 | (0.39) | (0.31) | (1.10) | (2.28) | 3.69 | (1.35) | (3.03) |
P/B ratio |
0.00 | 0.00 | 0.00 | 24.40 | 7.05 | 8.81 | 9.67 | 7.78 | 6.32 | 2.71 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 24.85 | 7.09 | 8.87 | 9.73 | 7.88 | 6.45 | 2.76 |
EV/Sales |
16.22 | 21.07 | 25.41 | 121.11 | 725.97 | 973.61 | 389.93 | 179.72 | 646.19 | 64.62 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
216.68 | (25.02) | (14.50) | (12.50) | (13.52) | (24.93) | (29.64) | (13.70) | (10.40) | (4.95) |
EV/FCF |
257.17 | (24.99) | (14.43) | (12.38) | (12.78) | (23.50) | (28.80) | (13.44) | (10.29) | (4.89) |
Quick Ratio |
0.72 | 0.81 | 2.31 | 4.44 | 7.03 | 13.75 | 12.58 | 7.21 | 8.32 | 13.52 |
Current Ratio |
1.04 | 1.17 | 3.56 | 5.39 | 8.03 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
Net Debt/EBITDA |
(2.16) | (1.14) | (0.33) | 0.42 | 1.33 | 1.93 | 2.55 | 1.81 | 1.76 | 2.50 |
Debt/Assets |
66.93% | 72.63% | 66.07% | 46.65% | 9.27% | 10.01% | 5.41% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(5.35) | (8.10) | (3.74) | 1.93 | 0.11 | 0.12 | 0.06 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.59 | 0.36 | 0.28 | 0.04 | 0.01 | 0.01 | 0.03 | 0.04 | 0.01 | 0.03 |
Operating CF/Net income |
(0.24) | 0.81 | 0.97 | 0.85 | 1.09 | 0.65 | 0.81 | 1.07 | 0.77 | 0.88 |
Capex/Depreciation |
(0.48) | (0.03) | (0.13) | (0.28) | (1.57) | (1.75) | (0.77) | (3.01) | (1.28) | (0.99) |
Interest Coverage |
(0.66) | (2.79) | (10.34) | (11.13) | (115.52) | (4.09) | (185.69) | (1,218.45) | (8.11) | (23.43) |
| 172.80% | 300.75% | (870.08%) | (92.90%) | (45.30%) | (58.84%) | (48.86%) | (56.66%) | (68.81%) | (46.08%) | |
| (18.76%) | (37.71%) | (51.04%) | (50.54%) | (37.77%) | (50.99%) | (43.04%) | (49.95%) | (62.41%) | (42.51%) | |
ROIC |
(91.65%) | (91.04%) | (84,748.35%) | (968.11%) | (93.45%) | (94.80%) | (397.86%) | (4,420.67%) | 0.00% | 0.00% |
Return on Tangible Assets |
(122.55%) | (150.20%) | (78.16%) | (66.17%) | (46.13%) | (52.67%) | (35.84%) | (50.36%) | (67.55%) | (39.63%) |
Average Days of Receivables |
79.93 | 178.10 | 76.32 | 182.78 | 1,088.05 | 385.53 | 147.72 | 90.72 | 566.81 | 132.10 |
Research and Development Expense of Revenue |
42.16% | 84.43% | 155.02% | 741.83% | 3,803.88% | 3,752.40% | 1,432.68% | 1,325.78% | 6,508.93% | 1,433.39% |
Selling, General and Administrative Expense of Revenue |
63.58% | 80.06% | 99.13% | 432.30% | 2,059.39% | 1,102.68% | 362.42% | 236.81% | 881.16% | 249.76% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
Share Based Compensation of Revenue |
16.13% | 26.27% | 24.99% | 125.42% | 859.21% | 764.71% | 280.27% | 185.73% | 634.56% | 158.94% |
Graham Net Nets |
(0.03) | (0.03) | (0.04) | 0.02 | 0.10 | 0.08 | 0.09 | 0.12 | 0.15 | 0.36 |
Graham Number |
16.95 | 17.77 | 24.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(1.97%) | (5.16%) | (7.25%) | (8.99%) | (6.16%) | (5.68%) | (3.80%) | (6.03%) | (10.48%) | (14.31%) |
Free Cash Flow Yield |
0.40% | (4.16%) | (7.08%) | (7.79%) | (7.10%) | (3.90%) | (3.13%) | (6.49%) | (8.11%) | (12.73%) |
Revenue per Share |
13.44 | 6.80 | 5.13 | 0.96 | 0.17 | 0.16 | 0.32 | 0.30 | 0.05 | 0.19 |
Operating CF per Share |
1.01 | (5.72) | (8.99) | (9.31) | (9.02) | (6.13) | (4.24) | (3.99) | (3.20) | (2.51) |
Capex per Share |
(0.16) | (0.01) | (0.05) | (0.09) | (0.52) | (0.37) | (0.12) | (0.08) | (0.03) | (0.03) |
Free Cash Flow per Share |
0.85 | (5.73) | (9.03) | (9.41) | (9.54) | (6.50) | (4.36) | (4.07) | (3.23) | (2.53) |
Cash per Share |
11.50 | 10.46 | 7.68 | 13.82 | 14.73 | 16.22 | 14.40 | 7.99 | 6.57 | 7.51 |
Shareholders Equity per Share |
(3.04) | (1.98) | (2.80) | 4.95 | 19.09 | 18.93 | 14.38 | 8.05 | 6.29 | 7.36 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(3.04) | (1.98) | (2.80) | 4.95 | 19.09 | 18.93 | 14.38 | 8.05 | 6.29 | 7.36 |
Free Cash Flow |
51.38 | (331.85) | (508.41) | (527.49) | (522.79) | (329.03) | (202.83) | (167.05) | (108.55) | (67.34) |
Working Capital |
44.80 | 165.56 | 546.97 | 792.52 | 834.71 | 785.14 | 630.76 | 299.96 | 204.43 | 188.68 |
Capital Expenditures |
(9.60) | (0.52) | (2.59) | (5.22) | (28.67) | (18.85) | (5.78) | (3.13) | (1.06) | (0.74) |
Net Current Asset Value |
(403.24) | (242.76) | (290.67) | 102.28 | 715.30 | 684.30 | 595.33 | 299.96 | 204.43 | 188.68 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.10 | 3.12 | 2.37 | 0.39 | 0.25 | 0.62 | 0.15 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.18 | 0.17 | 0.14 | 0.12 | 0.09 | 0.15 | 0.20 | 0.29 | 0.29 |
Cash ROIC |
3.43% | (23.40%) | (58.78%) | (33.22%) | (26.52%) | (17.40%) | (14.70%) | (25.35%) | (25.10%) | (17.05%) |
Accounts Receivable Turnover |
4.40 | 3.12 | 6.61 | 1.98 | 0.51 | 1.10 | 3.27 | 4.32 | 0.76 | 2.39 |
Accounts Payable Turnover |
1.04 | 0.46 | 0.46 | 0.14 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.32 | 0.18 | 0.26 | 0.11 | 0.00 | — | — | — | — | — |
Average Days of Payables |
348.63 | 794.97 | 777.49 | 3,038.38 | 6,155.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
1,159.56 | 2,437.92 | 1,717.76 | 3,929.79 | 7,812.26 | — | — | — | — | — |
Average Receivables |
185.21 | 126.19 | 43.68 | 27.22 | 17.91 | 7.23 | 4.58 | 2.90 | 2.27 | 2.14 |
Average Payables |
103.44 | 103.33 | 104.40 | 88.37 | 47.65 | 28.05 | 27.20 | 25.09 | 20.67 | 11.88 |
Average Inventory |
330.52 | 273.00 | 181.90 | 113.44 | — | — | — | — | — | — |
Average Assets |
1,375.03 | 1,084.93 | 1,020.84 | 1,215.86 | 1,201.39 | 938.58 | 567.32 | 307.59 | 224.40 | 178.33 |
Average Common Equity |
(149.30) | (136.04) | 59.89 | 661.45 | 1,001.74 | 813.41 | 499.75 | 271.17 | 203.52 | 164.53 |
Columns are period end dates